Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions

ISSN： 1699-048X

Source： Clinical and Translational Oncology, Vol.13, Iss.9, 2011-09, pp. : 629-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant chemoradiotherapy for stage III (N2/3) non-small-cell lung cancer: a review of prospective studies

By Robinson Cliff Stephans Kevin

Lung Cancer Management, Vol. 2, Iss. 1, 2013-02 ,pp. : 47-60

Future Medicine

Access to resources Recommend Favorite

By Campian Jian L. Ye Xiaobu Brock Malcolm Grossman Stuart A.

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 183-188

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care

By Laskin Janessa J

Future Oncology, Vol. 1, Iss. 5, 2005-10 ,pp. : 619-623

Future Medicine

Access to resources Recommend Favorite

NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Oncology Letters, Vol. 10, Iss. 3, 2015-01 ,pp. : 1533-1540

Spandidos Publications

Access to resources Recommend Favorite

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

By Casal Rubio J. Fírvida-Pérez J. Lázaro-Quintela M. Barón-Duarte F. Alonso-Jáudenes G. Santomé L. Afonso-Afonso F. Amenedo M. Huidobro G. Campos-Balea B. López-Vázquez M. Vázquez S.

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 451-457

Springer Publishing Company

Access to resources Recommend Favorite